BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15640844)

  • 1. Polo-like kinases (Plks) and cancer.
    Takai N; Hamanaka R; Yoshimatsu J; Miyakawa I
    Oncogene; 2005 Jan; 24(2):287-91. PubMed ID: 15640844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinases and the microtubule organization center: targets for cancer therapies.
    Dai W; Cogswell JP
    Prog Cell Cycle Res; 2003; 5():327-34. PubMed ID: 14593727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
    Jang YJ; Kim YS; Kim WH
    Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
    Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
    Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinases and oncogenesis.
    Eckerdt F; Yuan J; Strebhardt K
    Oncogene; 2005 Jan; 24(2):267-76. PubMed ID: 15640842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
    Ahmad N
    FASEB J; 2004 Jan; 18(1):5-7. PubMed ID: 14718382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
    Chopra P; Sethi G; Dastidar SG; Ray A
    Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma.
    Weichert W; Denkert C; Schmidt M; Gekeler V; Wolf G; Köbel M; Dietel M; Hauptmann S
    Br J Cancer; 2004 Feb; 90(4):815-21. PubMed ID: 14970859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitotic kinases: the key to duplication, segregation, and cytokinesis errors, chromosomal instability, and oncogenesis.
    Li JJ; Li SA
    Pharmacol Ther; 2006 Sep; 111(3):974-84. PubMed ID: 16603252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity.
    Oshimori N; Ohsugi M; Yamamoto T
    Nat Cell Biol; 2006 Oct; 8(10):1095-101. PubMed ID: 16980960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-box motif targets a centrosome regulator, RanGTPase.
    Jang YJ; Ji JH; Ahn JH; Hoe KL; Won M; Im DS; Chae SK; Song S; Yoo HS
    Biochem Biophys Res Commun; 2004 Dec; 325(1):257-64. PubMed ID: 15522227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinases and centrosome regulation.
    Dai W; Wang Q; Traganos F
    Oncogene; 2002 Sep; 21(40):6195-200. PubMed ID: 12214249
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
    Winkles JA; Alberts GF
    Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Polo like kinase 1 expression and prognostic value in gastric carcinomas].
    Lan B; Liu BY; Chen XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jan; 10(1):70-2. PubMed ID: 17253180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
    Zhou Q; Bai M; Su Y
    Chin Med J (Engl); 2004 Nov; 117(11):1642-9. PubMed ID: 15569479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intense nanosecond pulsed electric fields promote cancer cell apoptosis through centrosome-dependent pathway involving reduced level of PLK1.
    Zou H; Gan XL; Linghu LJ; Chen C; Hu LN; Zhang Y
    Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):152-60. PubMed ID: 23377802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.
    Astrinidis A; Senapedis W; Henske EP
    Hum Mol Genet; 2006 Jan; 15(2):287-97. PubMed ID: 16339216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting in and out of mitosis with Polo-like kinase-1.
    van Vugt MA; Medema RH
    Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.